Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening
- Conditions
- Colorectal Cancer
- Interventions
- Behavioral: Visit-Based Nudge/TextBehavioral: No Direct Patient OutreachBehavioral: No Nudge/Text
- Registration Number
- NCT05693649
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Brief Summary
This is a 3-year pragmatic, randomized clinical trial among average-risk patients at diverse primary care practices who are overdue for colorectal (CRC) screening. This project aims to evaluate the effect of a centralized program that includes direct outreach to patients and visit-based, clinician directed nudges facilitated by the electronic health record (EHR) with follow-up text messaging on the uptake of CRC screening. The primary outcome is CRC screening completion at 3 years. Patient and clinician factors impacting the experience and effectiveness of the intervention will be explored through surveys and qualitative interviews.
- Detailed Description
Despite effective strategies for prevention, early detection, and treatment, colorectal cancer (CRC) remains the second leading cause of cancer death in the United States (US). While there have been considerable policy and system-level efforts to increase CRC screening rates, uptake remains well below national goals of 80% participation. Members of racial and ethnic minorities are even further behind. Approaches to increase population-based screening can consider \[1\] how screening is encouraged by targeting the clinicians who typically order or recommend the procedure or the patient who completes it; and \[2\] the kind of screening offered (e.g., colonoscopy or fecal immunochemical testing \[FIT\]). This project simultaneously tests interventions along both of these dimensions.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 20000
- Patients ages 50-72
- Followed by Primary Care with a participating Penn Medicine PCP listed and at least one visit in the last 2 years
- Not up to date on colorectal cancer screening per Health Maintenance (no colonoscopy in the last 10 years, stool testing in the last year, flexible sigmoidoscopy in the last 5 years, MT-sDNA in the last 3 years).
- Personal or significant family history of CRC, colonic polyps, hereditary nonpolyposis colorectal cancer syndrome, familial adenomatous polyposis syndrome, other gastrointestinal cancer, gastrointestinal bleeding, iron-deficiency anemia, or inflammatory bowel disease
- History of total colectomy, dementia or metastatic cancer
- Currently on hospice or receiving palliative care
- Uninsured or self-pay patients
- Currently scheduled for a colonoscopy or sigmoidoscopy
- Active order for multitarget stool DNA testing (MT-sDNA)
- History of paraplegia or quadriplegia
- Elevated chance of mortality within 3 years according to mortality risk algorithm
- Active order for Fecal Immunochemical Test (FIT) in the last 60 days
- Positive stool test (FIT or MT-sDNA) result in the last 5 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Arm 1A: Usual Care No Nudge/Text Patients assigned to the Usual Care arm will receive current usual care and will not receive direct patient outreach or any visit-based interventions from this trial. Arm 3B: Sequential Choice and Visit-Based Nudge/Text Visit-Based Nudge/Text Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion. Arm 1A: Usual Care No Direct Patient Outreach Patients assigned to the Usual Care arm will receive current usual care and will not receive direct patient outreach or any visit-based interventions from this trial. Arm 2B: Colonoscopy Only and Visit-Based Nudge/Text Visit-Based Nudge/Text Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion. Arm 2A: Colonoscopy Only and No Nudge/Text No Nudge/Text Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm will not receive visit-based interventions. Arm 3A: Sequential Choice and No Nudge/Text No Nudge/Text Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm will not receive visit-based interventions.
- Primary Outcome Measures
Name Time Method CRC screening completion at 3 years 3 years CRC screening completion at 3 years, which could be satisfied by any one of the following: colonoscopy completion at any time, negative FIT completed 2 times, or positive FIT followed by diagnostic colonoscopy within 1 year.
- Secondary Outcome Measures
Name Time Method Choice of test 3 years The proportion of patients who complete CRC screening by screening type
CRC screening rate 3 years CRC screening completion at 3 years by any modality
Trial Locations
- Locations (1)
Penn Medicine
🇺🇸Philadelphia, Pennsylvania, United States